Acta Scientific Cancer Biology (ASCB)

Review Article Volume 4 Issue 1

Glioblastoma - Application of Gene Therapy During A Quarter of A Century: Anti - Gene IGF-I Strategy

Gabriela Quintero1,2, Andrea Guzman2, Diana M Gomez2,3, Heliodor Kasprzak2,4, Pedro Penagos2,5, Heber Siachoque2,6, Alexander Shevelev2,7, Annabelle Trojan2,8, Alvaro Alvarez2,8 and Jerzy Trojan2,6,9*

1Faculty of Medicine, UNAB University, Floridablanca, Colombia
2ICGT – International Cancer Gene Therapy, Bogota / Paris, Colombia and France
3Faculty of Science, Dept. Chemistry, UN – National University, Bogota, Colombia
4Faculty of Medicine, UMK – Nicolaus Copernic University, Torun, Poland
5Dept. Neurosurgery, INC – National Cancer Institute, Bogota, Colombia
6CEDEA – Center of Oncologic Diagnostic, Bogota, Colombia
7Laboratory of Cell Engineering, Indust. Res. Complex, Moscow, Russia
8Faculty of Medicine, University of Cartagena, Cartagena de Indias, Colombia
9INSERM U602, Cancer Center, Villejuif, France

*Corresponding Author: Gabriela Quintero, Faculty of Medicine, UNAB, Floridablanca, Colombia and Jerzy Trojan, ICGT – International Cancer Gene Therapy, Bogota / Paris, Colombia and France.

Received: November 05, 2019; Published: December 10, 2019



   This review gives an example of current recommended post-surgery treatment of malignant brain tumor – glioblastoma whose prognostic is always fatal. In this striking area of neuro-oncology, despite the use of modern approaches of surgery, radiotherapy, hormonotherapy and especially chemotherapy, the results are still far from our expectations. Two years ago, the government of USA has approved the Moonshot program which recommends the introduction in oncology, as an obligatory challenge, of immunotherapy – the domain based on basic science of molecular biology, genetics and immunology. In this article we have described general ideas and clinical results of cancer gene therapy, being also cancer immunogen therapy, which has showed the promising results as follows. In cancer cells provided from surgical biopsy, the expression of IGF-I, principal growth factor responsible of neoplastic development, was suppressed using anti – gene technology. These genetically modified cancer cells, playing the role of vaccines, while injected subcutaneously in cancer patients, induced an immune anti – response, mediated by lymphocytes CD8. During last twenty-five years, the malignant tumors, principally glioblastoma, were treated using anti - gene IGF-I therapy. The median survival of treated patients has reached 20 months, and in some case 3 and 4 years. (Using classical treatment, including chemotherapy, the median survival is maximum 14 month, rarely 18 months).

Keywords: Cancer Gene Therapy; Glioblastoma; Antisense; Triple Helix; IGF-I; Lymphocytes TCD 8 And 28



  1. panel/blue-ribbon-panel-report-2016.pdf
  2. Coley WB. “The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases”. American Journal of Medical Science 105 (1893): 48. 
  3. Anderson WF., et al. “The ADA human gene therapy clinical protocol: Points to consider response with clinical protocol”. Human Gene Therapy 1.3 (1990): 331-362.
  4. Trojan J., et al. “Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense Insulin like Growth Factor I RNA”. Science 259 (1993): 94-97. 
  5. Townsend SE and Allison JA. “Tumor rejection after direct costi-mulation of CD8+ T cell transfected melanoma cells”. Science 259 (1993): 368-370.  
  6. Guo Y., et al. “Effective tumor vaccine generated by fusion of hepatoma cells with lymphocytes B cells”. Science 263 (1994): 518-520. 
  7. Dietrich PY., et al. “T-cell immunotherapy for malignant glioma: toward a combined approach”. Current Opinion in Oncology 22 (2010): 604-610.
  8. Dalotto-Moreno T., et al. “Immunotherapy of cancer: Actual perspectives, challenges and new horizons (in Spanish)”. Medicina (Buenos Aires) 78.5 (2018): 336-348. 
  9. Siegel RL., et al. “Statistic of cancer”. CA: A Cancer Journal for Clinicians 69 (2019): 7-34.  
  10. Bueno SJ., et al. “Brain stem cells and IGF-I: implications in development, regeneration and cancer therapeutics”. Integrative Molecular Medicine 5.1 (2018): 1-7.
  11. Feinberg AP. “The key role of epigenetics in human disease prevention and mitigation”. New England Journal of Medicine 378.14 (2018): 1323-1334. 
  12. Trojan A., et al. “Testing of IGF-I biomarker in an ethical context”. Advances in Modern Oncology Research 2.4 (2016). 
  13. Dervan P. “Reagents for the site specific cleavage of megabase DNA”. Nature 359 (1992): 87-88.  
  14. Trojan J., et al. “IGF-I biology and targeting in malignant glioma”. Neuroscience 145.3 (2007): 795-811.
  15. Trojan J. “Brain - from development to neoplasia and gene therapy solution”. Ed. Lambert Academic Publishers, Germany 2017/2018 1-150. 
  16. Soltani K. “Alpha-Fetoprotein: A Review”. Journal of Investigative Dermatology 72 (1979):211-213.
  17. Trojan J., et al. “Immunocytochemical quantitative study of alphafetoprotein in normal and neoplastic neural development”. Developmental Neuroscience 6 (1984): 251-259.
  18. Van den Brande JL. “Plasma somatomedin. Clinical observations”. In: A. Pecile and E.E. Muller “Growth hormones and related peptides”, Ed. Excerpta Medica, Amsterdam, 1976, pp 271-285. 
  19. Le Roith D. “The insulin-like growth factor system”. Experimental Diabesity Research 4 (2003): 205-212. 
  20. Baserga R. “The insulin-like growth factor-I receptor as a target for cancer therapy”. Expert Opinion in Therapy Targets 9 (2005): 753-768. 
  21. Chen H., et al. “Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes”. Journal of Clinical Endocrinology and Metabolism 99.9 (2014): E1635-1640.  
  22. Pollak MN., et al. “Insulin-like growth factors and neoplasia”. Nature Review Cancer 4 (2004): 505-518.  
  23. Mason JL. et al. “Insulin-Like Growth Factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination”. Journal of Neuroscience 20.15 (2000): 5703-5708. 
  24. Yongping You. “Targets in gene therapy”, Ed. In Tech Open, Rijeka, Croatia (2011).
  25. Contreras LE. “Epidemiology of brain tumors (in Spanish)”. Revista Médica Clínica Las Condes 28.3 (2017): 332-338. 
  26. Ly A., et al. “Expression of IGF-I in glioma cells is associated with change in both immunogenicity and apoptosis”. Neuroscience Letters 281 (2000): 13-16.
  27. Arcaro A. “Targeting the insulin-like growth factor-1 receptor in human cancer”. Front of Pharmacology 4.30 (2013).
  28. Trojan J., et al. “Loss of tumorogenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I”. Proceedings of National Academy of Science USA 89.11 (1992): 4874-4878.
  29. Louis DN., et al. “The 2007 WHO classification of tumours of the central nervous system”. Acta of Neuropathology 114.2 (2007): 97-109.
  30. Huttner A. “Overview of primary brain tumors pathologic classification, epidemiology, molecular biology, and prognostic markers”. Hematology/ Oncology Clinics of North America 26 (2012): 715–732.
  31. Ostrom QT., et al. “CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2009-2013”. Neurology Oncology 18.5 (2016): v1-v75.
  32. Trojan J. “Cancer immunogene therapy”. Anti - gene anti IGF-I approach. Case of glioblastoma”. Edition. Lambert Academic Publishers, Germany (2017): 1-140. 
  33. Trojan J., et al. “Gene therapy of murine teratocarcinoma: Separate functions for insulin-like growth factors I and II in immunogenicity and differentiation”. Proceedings of National Academy of Science USA 91 (1994): 6088-6092.
  34. Shevelev A., et al. “Potential triple helix-mediated inhibition of IGF-I gene expression significantly reduces tumorigenicity of glioblastoma in an animal model”. Cancer Gene Therapy 4.2 (1997):105-112.  
  35. Hélène C. “Control of oncogene expression by antisense nucleic acid”. European Journal of Cancer 30.A (1994):1721-1726.  
  36. Rubenstein JL., et al. “Nonsense RNA: a tool for specifically inhibiting the expression of a gene In vivo”. Compte Rendu Academie de Science Paris III 299 (1984): 271-274.
  37. Weintraub H., et al. “Antisense RNA as a molecular tool for genetic analysis”. Trends in Genetics 1.1(1985): 23-25.  
  38. Green PJ., et al. “The role of antisense RNA in gene regulation”. Annales Review of Biochemistry 55 (1986): 569-597.
  39. Culver KW., et al. “In vivo gene transfer with retroviral vector-producer celIs for treatment of experimental brain tumors”. Science 256 (1992): 1550-1552. 
  40. Resnicoff R., et al. “Rat glioblastoma cells expressing an antisens RNA to the insulin-like growth factor receptor are non-tumorigenic and induce regression of wild-type tumors”. Cancer Research 54 (1994): 2218-2222. 
  41. Trojan J., et al. “Methodology for anti - gene anti - IGF-I therapy of malignant tumours”. Chemotherapy Research and Practice (2012): 1-12. 
  42. Höppener JWM., et al. “The human gene encoding insulin-like growth factor I is located on chromosome 12”. Human Genetics 69 (1985): 157.
  43. Parsons DW., et al. “An integrated genomic analysis of human Glioblastoma Multiforme”. Science 321.5897 (2008): 1807-1812. 
  44. Wongkajornsilp A., et al. “The analysis of peri-tumour necrosis following the subcutaneous implantation of autologous tumor cells transfected with an episome transcribing an antisense IGF-I RNA in a glioblastoma multiforme subject”. Journal of Medical Association Thai 4.3 (2001):740-747. 
  45. Stupp R., et al. “Neuro-oncology, a decade of temozolomide and beyond”. Expert Review of Anticancer Therapy 10.11 (2010): 1675-1677. 
  46. Catuogno S., et al. “Nucleic acids in human glioma treatment: innovative approaches and recent results”. Journal of Signal Transduction (2012): 735135. 
  47. Caruso G and Caffo M. “Antisense oligonucleotides in the treatment of cerebral gliomas. Review of concern Ing patents”. Recent Patents on CNS Drug Discovery (2014).
  48. Le Corre SS., et al. “Cationic lipophosforamidates with two different lipid chains: synthesis and evalua tion as gene carriers”. Organic and Biomolecular Chemistry 12.9 (2014): 1463-1474. 
  49. Love S., et al. “Greenfield's Neuropathology”. E., NY: CRC Press (2015).


Citation: Gabriela Quintero, Jerzy Trojan., et al. “Glioblastoma - Application of Gene Therapy During A Quarter of A Century: Anti - Gene IGF-I Strategy”.Acta Scientific Cancer Biology 4.1 (2020): 38-45.

Member In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 15, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US